Well that was dumb lol.
I wouldn't risk lack of diversification from AT1 if they provide the core product for LDX product.
That and AT1 have other products in different markets also with existing deals.
I dont own AT1 myself and never bought in. Im just amazed that their pittance of a deal compared to LDX drove a 122% increase on open. LDX hasnt seen anything like that on their major deals outside of FDA approval.
Not even when we got the EUA with Viradx.
Once could assume that if they announce $1M worth of febridx sold this quarter, the SP would return back to .10c+ zone.
Add to My Watchlist
What is My Watchlist?
